JS-K; a nitric oxide-releasing prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism

Biochemical Pharmacology

Volumn 80, Issue 11, 2010, Pages 1641-1649

  Nath, Niharika ^a,b   Chattopadhyay, Mitali ^a   Pospishil, Liliya ^a   Cieciura, Lucyna Z ^a   Goswami, Satindra ^a   Kodela, Ravinder ^a   Saavedra, Joseph E ^c   Keefer, Larry K ^d   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Catenin; Chemoprevention; JS K; Leukemia; S nitrosylation

Indexed keywords

BETA CATENIN; CYCLIN D1; LACTATE DEHYDROGENASE; NITRIC OXIDE DONOR; NUCLEAR PROTEIN; O2 (2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; PRODRUG; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; ENZYME RELEASE; LEUKEMIA CELL LINE; NITROSYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; AZO COMPOUNDS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; GROWTH INHIBITORS; HUMANS; JURKAT CELLS; NITRIC OXIDE; NITROSO COMPOUNDS; PIPERAZINES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRODRUGS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 77957904600     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.011     Document Type: Article

References (44)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Faderl S., Kantarjian H.M., Talpaz M., Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998, 91:3995-4019.
3. Stefano F., Distrutti E. Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status. Curr Top Med Chem 2007, 7:277-282.
4. Li C.Q., Wogan G.N. Nitric oxide as a modulator of apoptosis. Cancer Lett 2005, 226:1-15.
5. Chung H.T., Pae H.O., Choi B.M., Billiar T.R., Kim Y.M. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 2001, 282:1075-1079.
6. Shami P.J., Saavedra J.E., Wang L.Y., Bonifant C.L., Diwan B.A., Singh S.V., et al. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2003, 2:409-417.
7. Shami P.J., Maciag A.E., Eddington J.K., Udupi V., Kosak K.M., Saavedra J.E., et al. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leuk Res 2009, 33:1525-1529.
8. Keefer L.K. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem 2005, 5:625-636.
9. Ren Z., Kar S., Wang Z., Wang M., Saavedra J.E., Carr B.I. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. J Cell Physiol 2003, 197:426-434.
10. Liu J., Li C., Qu W., Leslie E., Bonifant C.L., Buzard G.S., et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 2004, 3:709-714.
11. Kiziltepe T., Hideshima T., Ishitsuka K., Ocio E.M., Raje N., Catley L., et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007, 110:709-718.
12. Shami P.J., Saavedra J.E., Bonifant C.L., Chu J., Udupi V., Malaviya S., et al. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 2006, 49:4356-4366.
13. Chakrapani H., Kalathur R.C., Maciag A.E., Citro M.L., Ji X., Keefer L.K., et al. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorg Med Chem 2008, 16:9764-9771.
14. Chung E.J., Hwang S.G., Nguyen P., Lee S., Kim J.S., Kim J.W., et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002, 100:982-990.
15. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96:5522-5527.
16. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
17. Tsutsui J., Moriyama M., Arima N., Ohtsubo H., Tanaka H., Ozawa M. Expression of cadherin-catenin complexes in human leukemia cell lines. J Biochem 1996, 120:1034-1039.
18. Stamler J.S., Jaraki O., Osborne J., Simon D.I., Keaney J., Vita J., et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992, 89:7674-7677.
19. Stamler J.S., Simon D.I., Osborne J.A., Mullins M.E., Jaraki O., Michel T., et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992, 89:444-448.
20. Saavedra J.E., Srinivasan A., Bonifant C.L., Chu J., Shanklin A.P., Flippen-Anderson J.L., et al. The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions. J Org Chem 2001, 66:3090-3098.
21. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988, 115:61-69.
22. Jaffrey S.R., Snyder S.H. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001, 2001:pl1.
23. Li S., Whorton A.R. Regulation of protein tyrosine phosphatase 1B in intact cells by S-nitrosothiols. Arch Biochem Biophys 2003, 410:269-279.
24. Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdelatif K, Keefer LK, et al. Comparison between NO-ASA and NONO-ASA as safe anti-inflammatory, analgesic, antipyretic, anti-oxidant, prodrugs. J Pharmacol Exp Ther (2010) doi:10.1124/jpet.110.171017.
25. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000, 97:4262-4266.
26. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15:391-404.
27. Magrinat G., Mason S.N., Shami P.J., Weinberg J.B. Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 1992, 80:1880-1884.
28. Shami P.J., Moore J.O., Gockerman J.P., Hathorn J.W., Misukonis M.A., Weinberg J.B. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk Res 1995, 19:527-533.
29. Chakrapani H., Goodblatt M.M., Udupi V., Malaviya S., Shami P.J., Keefer L.K., et al. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound. Bioorg Med Chem Lett 2008, 18:950-953.
30. Nath N., Vassell R., Chattopadhyay M., Kogan M., Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol 2009, 78:1298-1304.
31. Royle J.S., Ross J.A., Ansell I., Bollina P., Tulloch D.N., Habib F.K. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004, 172:338-344.
32. Mijatovic S., Maksimovic-Ivanic D., Mojic M., Malaponte G., Libra M., Cardile V., et al. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 2008, 19:177-183.
33. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
34. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006, 8:1329-1337.
35. Roberts D.D., Isenberg J.S., Ridnour L.A., Wink D.A. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 2007, 13:795-798.
36. Kitagaki J., Yang Y., Saavedra J.E., Colburn N.H., Keefer L.K., Perantoni A.O. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene 2009, 28:619-624.
37. Cordes C.M., Bennett R.G., Siford G.L., Hamel F.G. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem Pharmacol 2009, 77:1064-1073.
38. Nath N., Kashfi K., Chen J., Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci USA 2003, 100:12584-12589.
39. Gao J., Liu X., Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 2005, 102:17207-17212.
40. Lane P., Hao G., Gross S.S. S-nitrosylation is emerging as a specific and fundamental posttranslational protein modification: head-to-head comparison with O-phosphorylation. Sci STKE 2001, 2001:re1.
41. Udupi V., Yu M., Malaviya S., Saavedra J.E., Shami P.J. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leuk Res 2006, 30:1279-1283.
42. Nath N., Labaze G., Rigas B., Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun 2005, 326:93-99.
43. Katayama N., Nakajou K., Ishima Y., Ikuta S., Yokoe J., Yoshida F., et al. Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. Nitric Oxide 2010, 22:259-265.
44. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.